BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khatib AM, Siegfried G, Chrétien M, Metrakos P, Seidah NG. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 2002;160:1921-35. [PMID: 12057895 DOI: 10.1016/S0002-9440(10)61140-6] [Cited by in Crossref: 153] [Cited by in F6Publishing: 66] [Article Influence: 8.1] [Reference Citation Analysis]
Number Citing Articles
1 Bergeron E, Basak A, Decroly E, Seidah NG. Pro-cessing of alpha4 integrin by the proprotein conver-tases: histidine at position P6 regulates cleavage. Biochem J. 2003;373:475-484. [PMID: 12691605 DOI: 10.1042/bj20021630] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
2 Caffrey M. HIV envelope: challenges and opportunities for development of entry inhibitors. Trends Microbiol 2011;19:191-7. [PMID: 21377881 DOI: 10.1016/j.tim.2011.02.001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 5.8] [Reference Citation Analysis]
3 Couture F, D'Anjou F, Day R. On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. Biomol Concepts 2011;2:421-38. [PMID: 22308173 DOI: 10.1515/bmc.2011.034] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
4 Siegfried G, Basak A, Cromlish JA, Benjannet S, Marcinkiewicz J, Chrétien M, Seidah NG, Khatib AM. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 2003;111:1723-32. [PMID: 12782675 DOI: 10.1172/JCI17220] [Cited by in Crossref: 11] [Cited by in F6Publishing: 70] [Article Influence: 0.6] [Reference Citation Analysis]
5 Bontemps Y, Scamuffa N, Calvo F, Khatib AM. Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases. Med Res Rev 2007;27:631-48. [PMID: 17019676 DOI: 10.1002/med.20072] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
6 Wu Y, Huang Y, Zhang W, Gunst SJ. The proprotein convertase furin inhibits IL-13-induced inflammation in airway smooth muscle by regulating integrin-associated signaling complexes. Am J Physiol Lung Cell Mol Physiol 2021;321:L102-15. [PMID: 34009050 DOI: 10.1152/ajplung.00618.2020] [Reference Citation Analysis]
7 Duval S, Abu-Thuraia A, Elkholi IE, Chen R, Seebun D, Mayne J, Côté JF, Figeys D, Seidah NG. Shedding of cancer susceptibility candidate 4 by the convertases PC7/furin unravels a novel secretory protein implicated in cancer progression. Cell Death Dis 2020;11:665. [PMID: 32820145 DOI: 10.1038/s41419-020-02893-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Fu J, Bassi DE, Zhang J, Li T, Nicolas E, Klein-Szanto AJ. Transgenic overexpression of the proprotein convertase furin enhances skin tumor growth. Neoplasia 2012;14:271-82. [PMID: 22577343 DOI: 10.1593/neo.12166] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
9 Coppola JM, Bhojani MS, Ross BD, Rehemtulla A. A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia 2008;10:363-70. [PMID: 18392131 DOI: 10.1593/neo.08166] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 5.8] [Reference Citation Analysis]
10 Rose M, Duhamel M, Aboulouard S, Kobeissy F, Tierny D, Fournier I, Rodet F, Salzet M. Therapeutic anti-glioma effect of the combined action of PCSK inhibitor with the anti-tumoral factors secreted by Poly (I:C)-stimulated macrophages. Cancer Gene Ther 2021. [PMID: 33402730 DOI: 10.1038/s41417-020-00286-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kwiatkowska A, Couture F, Ait-Mohand S, Desjardins R, Dory YL, Guérin B, Day R. Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug. Sci Rep 2019;9:2118. [PMID: 30765725 DOI: 10.1038/s41598-018-37568-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Heng S, Stephens AN, Jobling TW, Nie G. Measuring PC activity in endocervical swab may provide a simple and non-invasive method to detect endometrial cancer in post-menopausal women. Oncotarget 2016;7:46573-8. [PMID: 27374098 DOI: 10.18632/oncotarget.10287] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Qiu H, Tang X, Ma J, Shaverdashvili K, Zhang K, Bedogni B. Notch1 Autoactivation via Transcriptional Regulation of Furin, Which Sustains Notch1 Signaling by Processing Notch1-Activating Proteases ADAM10 and Membrane Type 1 Matrix Metalloproteinase. Mol Cell Biol 2015;35:3622-32. [PMID: 26283728 DOI: 10.1128/MCB.00116-15] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
14 Heni M, Haupt A, Schäfer SA, Ketterer C, Thamer C, Machicao F, Stefan N, Staiger H, Häring HU, Fritsche A. Association of obesity risk SNPs in PCSK1 with insulin sensitivity and proinsulin conversion. BMC Med Genet 2010;11:86. [PMID: 20534142 DOI: 10.1186/1471-2350-11-86] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
15 Shakya M, Lindberg I. Mouse Models of Human Proprotein Convertase Insufficiency. Endocr Rev 2021;42:259-94. [PMID: 33382413 DOI: 10.1210/endrev/bnaa033] [Reference Citation Analysis]
16 Parvaz N, Jalali Z. Molecular evolution of PCSK family: Analysis of natural selection rate and gene loss. PLoS One 2021;16:e0259085. [PMID: 34710160 DOI: 10.1371/journal.pone.0259085] [Reference Citation Analysis]
17 Müller EJ, Caldelari R, Posthaus H. Role of subtilisin-like convertases in cadherin processing or the conundrum to stall cadherin function by convertase inhibitors in cancer therapy. J Mol Histol 2004;35:263-75. [PMID: 15339046 DOI: 10.1023/b:hijo.0000032358.51866.a2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
18 Maret D, Sadr MS, Sadr ES, Colman DR, Del Maestro RF, Seidah NG. Opposite roles of furin and PC5A in N-cadherin processing. Neoplasia 2012;14:880-92. [PMID: 23097623 DOI: 10.1593/neo.121250] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
19 Dianati V, Navals P, Couture F, Desjardins R, Dame A, Kwiatkowska A, Day R, Dory YL. Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue. J Med Chem 2018;61:11250-60. [PMID: 30501188 DOI: 10.1021/acs.jmedchem.8b01381] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
20 Gawlik K, Shiryaev SA, Zhu W, Motamedchaboki K, Desjardins R, Day R, Remacle AG, Stec B, Strongin AY. Autocatalytic activation of the furin zymogen requires removal of the emerging enzyme's N-terminus from the active site. PLoS One 2009;4:e5031. [PMID: 19352504 DOI: 10.1371/journal.pone.0005031] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
21 Couture F, D'Anjou F, Desjardins R, Boudreau F, Day R. Role of proprotein convertases in prostate cancer progression. Neoplasia 2012;14:1032-42. [PMID: 23226097 DOI: 10.1593/neo.121368] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
22 Fu J, Zhang J, Gong Y, Testa CL, Klein-Szanto AJ. Regulation of HIF-1 alpha by the proprotein convertases furin and PC7 in human squamous carcinoma cells. Mol Carcinog 2015;54:698-706. [PMID: 24436242 DOI: 10.1002/mc.22131] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
23 Rose M, Duhamel M, Rodet F, Salzet M. The Role of Proprotein Convertases in the Regulation of the Function of Immune Cells in the Oncoimmune Response. Front Immunol 2021;12:667850. [PMID: 33995401 DOI: 10.3389/fimmu.2021.667850] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Sun X, Essalmani R, Seidah NG, Prat A. The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model. Mol Cancer 2009;8:73. [PMID: 19737405 DOI: 10.1186/1476-4598-8-73] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
25 Fradet L, Temmar R, Couture F, Belzile M, Fortier PH, Day R. Evaluation of PACE4 isoforms as biomarkers in thyroid cancer. J Otolaryngol Head Neck Surg 2018;47:63. [PMID: 30340539 DOI: 10.1186/s40463-018-0311-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Fu J, Bassi DE, Zhang J, Li T, Cai KQ, Testa CL, Nicolas E, Klein-Szanto AJ. Enhanced UV-induced skin carcinogenesis in transgenic mice overexpressing proprotein convertases. Neoplasia 2013;15:169-79. [PMID: 23441131 DOI: 10.1593/neo.121846] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
27 Siegfried G, Descarpentrie J, Evrard S, Khatib AM. Proprotein convertases: Key players in inflammation-related malignancies and metastasis. Cancer Lett 2020;473:50-61. [PMID: 31899298 DOI: 10.1016/j.canlet.2019.12.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
28 Lee SN, Choi IS, Kim HJ, Yang EJ, Min HJ, Yoon JH. Proprotein convertase inhibition promotes ciliated cell differentiation - a potential mechanism for the inhibition of Notch1 signalling by decanoyl-RVKR-chloromethylketone. J Tissue Eng Regen Med 2017;11:2667-80. [PMID: 27878968 DOI: 10.1002/term.2240] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
29 Wheatley JL, Holyoak T. Differential P1 arginine and lysine recognition in the prototypical proprotein convertase Kex2. Proc Natl Acad Sci U S A 2007;104:6626-31. [PMID: 17426142 DOI: 10.1073/pnas.0701983104] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
30 Karnezis T, Shayan R, Fox S, Achen MG, Stacker SA. The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget 2012;3:893-906. [PMID: 23097685 DOI: 10.18632/oncotarget.593] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
31 Sun X, Essalmani R, Day R, Khatib AM, Seidah NG, Prat A. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia 2012;14:1122-31. [PMID: 23308045 DOI: 10.1593/neo.121252] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 6.6] [Reference Citation Analysis]
32 Grice DM, Vetter I, Faddy HM, Kenny PA, Roberts-Thomson SJ, Monteith GR. Golgi calcium pump secretory pathway calcium ATPase 1 (SPCA1) is a key regulator of insulin-like growth factor receptor (IGF1R) processing in the basal-like breast cancer cell line MDA-MB-231. J Biol Chem 2010;285:37458-66. [PMID: 20837466 DOI: 10.1074/jbc.M110.163329] [Cited by in Crossref: 65] [Cited by in F6Publishing: 32] [Article Influence: 5.9] [Reference Citation Analysis]
33 Zhou B, Gao S. Pan-Cancer Analysis of FURIN as a Potential Prognostic and Immunological Biomarker. Front Mol Biosci 2021;8:648402. [PMID: 33968987 DOI: 10.3389/fmolb.2021.648402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Nejjari M, Berthet V, Rigot V, Laforest S, Jacquier MF, Seidah NG, Remy L, Bruyneel E, Scoazec JY, Marvaldi J, Luis J. Inhibition of proprotein convertases enhances cell migration and metastases development of human colon carcinoma cells in a rat model. Am J Pathol 2004;164:1925-33. [PMID: 15161629 DOI: 10.1016/S0002-9440(10)63753-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
35 Couture F, Ly K, Levesque C, Kwiatkowska A, Ait-Mohand S, Desjardins R, Guérin B, Day R. Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity. Biomed Res Int 2015;2015:824014. [PMID: 26114115 DOI: 10.1155/2015/824014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
36 Hook V, Funkelstein L, Lu D, Bark S, Wegrzyn J, Hwang SR. Proteases for processing proneuropeptides into peptide neurotransmitters and hormones. Annu Rev Pharmacol Toxicol 2008;48:393-423. [PMID: 18184105 DOI: 10.1146/annurev.pharmtox.48.113006.094812] [Cited by in Crossref: 171] [Cited by in F6Publishing: 151] [Article Influence: 13.2] [Reference Citation Analysis]
37 Tang SS, Zhang JH, Liu HX, Li HZ. PC2/CPE-mediated pro-protein processing in tumor cells and its differentiated cells or tissues. Mol Cell Endocrinol 2009;303:43-9. [PMID: 19428990 DOI: 10.1016/j.mce.2009.01.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
38 D'Anjou F, Routhier S, Perreault JP, Latil A, Bonnel D, Fournier I, Salzet M, Day R. Molecular Validation of PACE4 as a Target in Prostate Cancer. Transl Oncol 2011;4:157-72. [PMID: 21633671 DOI: 10.1593/tlo.10295] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
39 Bentele C, Krüger O, Tödtmann U, Oley M, Ragg H. A proprotein convertase-inhibiting serpin with an endoplasmic reticulum targeting signal from Branchiostoma lanceolatum, a close relative of vertebrates. Biochem J 2006;395:449-56. [PMID: 16445382 DOI: 10.1042/BJ20051947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
40 Longuespée R, Couture F, Levesque C, Kwiatkowska A, Desjardins R, Gagnon S, Vergara D, Maffia M, Fournier I, Salzet M, Day R. Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. Transl Oncol 2014:S1936-5233(14)00043-6. [PMID: 24818756 DOI: 10.1016/j.tranon.2014.04.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
41 Tang SS, Zhang JH, Liu HX, Zhou D, Qi R. Pro-protein convertase-2/carboxypeptidase-E mediated neuropeptide processing of RGC-5 cell after in vitro ischemia. Neurosci Bull 2009;25:7-14. [PMID: 19190683 DOI: 10.1007/s12264-009-1027-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
42 Basak A, Khatib AM, Mohottalage D, Basak S, Kolajova M, Bag SS, Basak A. A novel enediynyl peptide inhibitor of furin that blocks processing of proPDGF-A, B and proVEGF-C. PLoS One 2009;4:e7700. [PMID: 19956642 DOI: 10.1371/journal.pone.0007700] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
43 Sfaxi F, Scamuffa N, Lalou C, Ma J, Metrakos P, Siegfried G, Ragg H, Bikfalvi A, Calvo F, Khatib AM. Repression of liver colorectal metastasis by the serpin Spn4A a naturally occurring inhibitor of the constitutive secretory proprotein convertases. Oncotarget 2014;5:4195-210. [PMID: 24961901 DOI: 10.18632/oncotarget.1966] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
44 Lalou C, Scamuffa N, Mourah S, Plassa F, Podgorniak MP, Soufir N, Dumaz N, Calvo F, Basset-Seguin N, Khatib AM. Inhibition of the proprotein convertases represses the invasiveness of human primary melanoma cells with altered p53, CDKN2A and N-Ras genes. PLoS One 2010;5:e9992. [PMID: 20404912 DOI: 10.1371/journal.pone.0009992] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
45 Tang R, Rosen SD. Functional consequences of the subdomain organization of the sulfs. J Biol Chem 2009;284:21505-14. [PMID: 19520866 DOI: 10.1074/jbc.M109.028472] [Cited by in Crossref: 56] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
46 Mzhavia N, Pan H, Che FY, Fricker LD, Devi LA. Characterization of endothelin-converting enzyme-2. Implication for a role in the nonclassical processing of regulatory peptides. J Biol Chem 2003;278:14704-11. [PMID: 12560336 DOI: 10.1074/jbc.M211242200] [Cited by in Crossref: 36] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
47 Stilling GA, Bayliss JM, Jin L, Zhang H, Lloyd RV. Chromogranin A transcription and gene expression in Folliculostellate (TtT/GF) cells inhibit cell growth. Endocr Pathol 2005;16:173-86. [PMID: 16299400 DOI: 10.1385/ep:16:3:173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
48 Huang YH, Lin KH, Liao CH, Lai MW, Tseng YH, Yeh CT. Furin overexpression suppresses tumor growth and predicts a better postoperative disease-free survival in hepatocellular carcinoma. PLoS One 2012;7:e40738. [PMID: 22808247 DOI: 10.1371/journal.pone.0040738] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
49 Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11:367-383. [PMID: 22679642 DOI: 10.1038/nrd3699] [Cited by in Crossref: 480] [Cited by in F6Publishing: 459] [Article Influence: 53.3] [Reference Citation Analysis]
50 Paria K, Paul D, Chowdhury T, Pyne S, Chakraborty R, Mandal SM. Synergy of melanin and vitamin-D may play a fundamental role in preventing SARS-CoV-2 infections and halt COVID-19 by inactivating furin protease. Transl Med Commun 2020;5:21. [PMID: 33169107 DOI: 10.1186/s41231-020-00073-y] [Reference Citation Analysis]
51 Stein J, Shah R, Steiner DF, Dey A. RNAi-mediated silencing of prohormone convertase (PC) 5/6 expression leads to impairment in processing of cocaine- and amphetamine-regulated transcript (CART) precursor. Biochem J 2006;400:209-15. [PMID: 16800814 DOI: 10.1042/BJ20060506] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
52 López JJ, Siegfried G, Cantonero C, Soulet F, Descarpentrie J, Smani T, Badiola I, Pernot S, Evrard S, Rosado JA, Khatib AM. Furin Prodomain ppFurin Enhances Ca2+ Entry Through Orai and TRPC6 Channels' Activation in Breast Cancer Cells. Cancers (Basel) 2021;13:1670. [PMID: 33916304 DOI: 10.3390/cancers13071670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
53 Hajdin K, D'Alessandro V, Niggli FK, Schäfer BW, Bernasconi M. Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model. PLoS One 2010;5:e10445. [PMID: 20454619 DOI: 10.1371/journal.pone.0010445] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
54 Levesque C, Couture F, Kwiatkowska A, Desjardins R, Guérin B, Neugebauer WA, Day R. PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation. Oncotarget 2015;6:3680-93. [PMID: 25682874 DOI: 10.18632/oncotarget.2918] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
55 Ramos-Molina B, Lick AN, Nasrolahi Shirazi A, Oh D, Tiwari R, El-Sayed NS, Parang K, Lindberg I. Cationic Cell-Penetrating Peptides Are Potent Furin Inhibitors. PLoS One 2015;10:e0130417. [PMID: 26110264 DOI: 10.1371/journal.pone.0130417] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
56 Kenney S, Vistica DT, Stockwin LH, Burkett S, Hollingshead MG, Borgel SD, Butcher DO, Schrump DS, Shoemaker RH. ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma. J Pediatr Hematol Oncol 2011;33:360-8. [PMID: 21552147 DOI: 10.1097/MPH.0b013e3182002f9f] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
57 Lewandowska-Goch MA, Kwiatkowska A, Łepek T, Ly K, Navals P, Gagnon H, Dory YL, Prahl A, Day R. Design and Structure-Activity Relationship of a Potent Furin Inhibitor Derived from Influenza Hemagglutinin. ACS Med Chem Lett 2021;12:365-72. [PMID: 33738063 DOI: 10.1021/acsmedchemlett.0c00386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
58 Chou CL, Chen TJ, Lin CY, Lee SW, Wang SC, Chu SS, Yang CC. PCSK1 Overexpression in Rectal Cancer Correlates with Poor Response to Preoperative Chemoradiotherapy and Prognosis. Onco Targets Ther 2020;13:3141-50. [PMID: 32346297 DOI: 10.2147/OTT.S243750] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Maret D, Gruzglin E, Sadr MS, Siu V, Shan W, Koch AW, Seidah NG, Del Maestro RF, Colman DR. Surface expression of precursor N-cadherin promotes tumor cell invasion. Neoplasia 2010;12:1066-80. [PMID: 21170270 DOI: 10.1593/neo.10954] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
60 Yamada M, Hayashi H, Yuuki M, Matsushima N, Yuan B, Takagi N. Furin inhibitor protects against neuronal cell death induced by activated NMDA receptors. Sci Rep 2018;8:5212. [PMID: 29581474 DOI: 10.1038/s41598-018-23567-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
61 Jaaks P, D'Alessandro V, Grob N, Büel S, Hajdin K, Schäfer BW, Bernasconi M. The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion. PLoS One 2016;11:e0161396. [PMID: 27548722 DOI: 10.1371/journal.pone.0161396] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
62 Bassi DE, Zhang J, Cenna J, Litwin S, Cukierman E, Klein-Szanto AJ. Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis. Neoplasia 2010;12:516-26. [PMID: 20651981 DOI: 10.1593/neo.92030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
63 Remacle AG, Gawlik K, Golubkov VS, Cadwell GW, Liddington RC, Cieplak P, Millis SZ, Desjardins R, Routhier S, Yuan XW, Neugebauer WA, Day R, Strongin AY. Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. Int J Biochem Cell Biol 2010;42:987-95. [PMID: 20197107 DOI: 10.1016/j.biocel.2010.02.013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
64 Levesque C, Fugère M, Kwiatkowska A, Couture F, Desjardins R, Routhier S, Moussette P, Prahl A, Lammek B, Appel JR, Houghten RA, D'Anjou F, Dory YL, Neugebauer W, Day R. The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells. J Med Chem 2012;55:10501-11. [PMID: 23126600 DOI: 10.1021/jm3011178] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
65 Couture F, Levesque C, Dumulon-Perreault V, Ait-Mohand S, D'Anjou F, Day R, Guérin B. PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor. Neoplasia 2014;16:634-43. [PMID: 25220591 DOI: 10.1016/j.neo.2014.07.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
66 Rose M, Duhamel M, Aboulouard S, Kobeissy F, Le Rhun E, Desmons A, Tierny D, Fournier I, Rodet F, Salzet M. The Role of a Proprotein Convertase Inhibitor in Reactivation of Tumor-Associated Macrophages and Inhibition of Glioma Growth. Mol Ther Oncolytics 2020;17:31-46. [PMID: 32300641 DOI: 10.1016/j.omto.2020.03.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]